Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAP-FLU ME is an investigational topical micro-emulsion developed by Mansoura University for the treatment of acne vulgaris. It is a combination therapy consisting of dapsone (5%), an antibacterial and anti-inflammatory agent, and flutamide (2.5%), an anti-androgenic agent. The formulation is an oil-in-water micro-emulsion that also incorporates natural ingredients like tea tree oil (5%) and rose oil, which provide additional antimicrobial and soothing effects. By targeting multiple pathogenic factors—including androgen-driven sebum production, bacterial colonization (specifically *Staphylococcus aureus*), and inflammatory cytokines like interleukin 1β—DAP-FLU ME aims to provide a comprehensive treatment for mild to moderate acne while minimizing the systemic side effects typically associated with oral administration of its active components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DAP-FLU ME.